Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Completed 92Terminated 21Recruiting 12Unknown 9Active not recruiting 9Withdrawn 5Not yet recruiting 3Suspended 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 10Ovarian Neoplasms 9Triple Negative Breast Neoplasms 8Endometrial Neoplasms 8Uterine Cervical Neoplasms 5Esophageal Neoplasms 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Fallopian Tube Neoplasms 4Pancreatic Neoplasms 3Neoplasms 3Small Cell Lung Carcinoma 2Recurrence 2NSCLC 2Mouth Neoplasms 2Laryngeal Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Ovarian Epithelial 2Unresectable Locally Advanced or Metastatic Solid Tumors 1Thyroid Neoplasms 1Stage III and IV Ovarian Cancer 1Squamous Non-small Cell Lung Cancer 1Solid Tumor Cancer 1Sarcoma, Kaposi 1Respiratory Tract Neoplasms 1Platinum-sensitive Relapsed Ovarian Cancer 1Platinum-Resistant Primary Peritoneal Carcinoma 1Pancreatic Intraductal Neoplasms 1PDAC - Pancreatic Ductal Adenocarcinoma 1

Interventions

Exercise 8Standard of Care 5trametinib 3tislelizumab 3Radiotherapy 3Radiosurgery 3Palliative Care 3Paclitaxel 3Gemcitabine 3130-nm albumin-bound paclitaxel 3trastuzumab deruxtecan 2cemiplimab 2Therapeutics 2Surveys and Questionnaires 2Resistance Training 2Oxaliplatin 2Nivolumab 2Maintenance 2Immune Checkpoint Inhibitors 2Drug Therapy 2Cisplatin 2Carboplatin 2vedolizumab 1toripalimab 1surufatinib 1sparsentan 1sintilimab 1semaglutide 1posaconazole 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Neoplasms × Paclitaxel × Clear all
NCT07274384 2025-12-10

HYPERBOLIC

Università Vita-Salute San Raffaele

Phase 2 Not yet recruiting
74 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

NCT06904300 2025-06-05

Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer

Sun Yat-sen University

Phase 2 Not yet recruiting
110 enrolled
Tumor-Agnostic

Neoplasms

NCT06363708 2024-04-12

Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer

Zhongnan Hospital

Phase NA Not yet recruiting
20 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡